Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12072-020-10058-6 http://scihub22266oqcxt.onion/10.1007/s12072-020-10058-6 32734407!7391917!32734407     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Hepatol+Int 2020 ; 14 (5): 701-710 Nephropedia Template TP {{tp|p=32734407|t=2020. Effect of COVID-19 on patients with compensated chronic liver diseases |pdf=|usr=}}{{32734407}} gab.com Text Effect of COVID-19 on patients with compensated chronic liver diseases JO: Hepatol Int http://www.kidney.de/pget.php?&tw=1&pmid=32734407 #FOAvip BACKGROUND AND AIM: Cytokine storm has been reported in patients with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. We examine the incidence of acute on chronic liver failure (ACLF) in COVID-19 patients with pre-existing compensated chronic liver disease (CLD). METHODS: From 20 Jan 2020 to 7 Feb 2020, we studied 140 consecutive COVID-19 patients admitted to either Fuyang Second People's Hospital (FYSPH), Anhui or the Fifth Medical Center of Chinese PLA General Hospital (PLAGH) in Beijing, China. Pre-existing CLD includes those with liver cirrhosis assessed by APRI/FIB-4 score and /or ultrasound; NAFLD as identified by either ultrasound or hepatic steatosis index with significant liver fibrosis and chronic hepatitis B (CHB) or hepatitis C (CHC) infection. The diagnosis, grading of severity and clinical management of COVID-19 patients complied to the guideline and clinical protocol issued by the China National Health Commission. All patients had liver function test at least twice weekly till discharge with full recovery or death. RESULTS: In total, 3 had liver cirrhosis, 6 patients had CHB, 13 had NAFLD with significant liver fibrosis (one also had CHB). On admission, none had liver decompensation. COVID-19 disease progression was significantly less frequent in non-CLD patients (10/118 8.5%) than CLD patients (13/22 59.1%, p < 0.001). One patient with CLD had acute-on-chronic liver failure (ACLF). CONCLUSION: Disease progression is significantly higher in those COVID-19 patients with CLD as compared to those with no CLD. ACLF can also occur in patient with pre-existing compensated CLD who had severe COVID-19. Twit Text FOAVip Effect of COVID-19 on patients with compensated chronic liver diseases ????Hepatol Int http://www.kidney.de/pget.php?&tw=1&pmid=32734407 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32734407 #FOAvip English Wikipedia <ref>{{Cite pmid|32734407}}</ref> Effect of COVID-19 on patients with compensated chronic liver diseases #MMPMID32734407 Ji D; Zhang D; Yang T; Mu J; Zhao P; Xu J; Li C; Cheng G; Wang Y; Chen Z; Qin E; Lau G Hepatol Int 2020[Sep]; 14 (5): 701-710 PMID32734407show ga BACKGROUND AND AIM: Cytokine storm has been reported in patients with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. We examine the incidence of acute on chronic liver failure (ACLF) in COVID-19 patients with pre-existing compensated chronic liver disease (CLD). METHODS: From 20 Jan 2020 to 7 Feb 2020, we studied 140 consecutive COVID-19 patients admitted to either Fuyang Second People's Hospital (FYSPH), Anhui or the Fifth Medical Center of Chinese PLA General Hospital (PLAGH) in Beijing, China. Pre-existing CLD includes those with liver cirrhosis assessed by APRI/FIB-4 score and /or ultrasound; NAFLD as identified by either ultrasound or hepatic steatosis index with significant liver fibrosis and chronic hepatitis B (CHB) or hepatitis C (CHC) infection. The diagnosis, grading of severity and clinical management of COVID-19 patients complied to the guideline and clinical protocol issued by the China National Health Commission. All patients had liver function test at least twice weekly till discharge with full recovery or death. RESULTS: In total, 3 had liver cirrhosis, 6 patients had CHB, 13 had NAFLD with significant liver fibrosis (one also had CHB). On admission, none had liver decompensation. COVID-19 disease progression was significantly less frequent in non-CLD patients (10/118 8.5%) than CLD patients (13/22 59.1%, p < 0.001). One patient with CLD had acute-on-chronic liver failure (ACLF). CONCLUSION: Disease progression is significantly higher in those COVID-19 patients with CLD as compared to those with no CLD. ACLF can also occur in patient with pre-existing compensated CLD who had severe COVID-19. |*Acute-On-Chronic Liver Failure/diagnosis/epidemiology/etiology[MESH] |*Coronavirus Infections/epidemiology/therapy[MESH] |*Hepatitis B, Chronic/complications/diagnosis[MESH] |*Liver Cirrhosis/diagnosis/epidemiology/etiology[MESH] |*Non-alcoholic Fatty Liver Disease/complications/diagnosis[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/epidemiology/therapy[MESH] |Betacoronavirus/isolation & purification[MESH] |COVID-19[MESH] |China/epidemiology[MESH] |Disease Progression[MESH] |Female[MESH] |Humans[MESH] |Incidence[MESH] |Liver Function Tests/methods[MESH] |Liver/diagnostic imaging[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2[MESH]Effect of COVID-19 on patients with compensated chronic liver diseases(epmc).pdf DeepDyve Pubget Overpricing